Versant & MPM Back Synthetic Lethality Newco With $68M
Executive Summary
Repare Therapeutics Inc., a Boston and Toronto-based cancer biotech, focusing on synthetic lethality, has hit the ground running with a $68m series A round from seasoned venture capitalists.